Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mycobacterium w + Docetaxel in Metastatic HRPC
NCT00525408Phase 2Terminated
- Sponsor
- Cadila Pharmaceuticals
- Start
- Nov 2007
- Primary completion
- Jan 2013
- Modality
- Prophylactic Vaccines, Microbiome Therapeutics, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of MYCIDAC-C in prostate cancer (PCa), sponsored by Cadila Pharmaceuticals. Started Nov 2007; status: terminated.
02
Drugs
MYCIDAC-C
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00525408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00525408.